International Society on Thrombosis and Haemostasis
2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura
Read the guideline
Abstract
Over the past few years, new information has emerged in the management of both immune thrombotic thrombocytopenic purpura (iTTP) and congenital (or hereditary) thrombotic thrombocytopenic purpura (cTTP).
In March 2024, the International Society on Thrombosis and Haemostasis (ISTH) formed a multidisciplinary panel comprising hematologists, intensivists, nephrologists, pathologists, patient representatives, and a methodology team. The panel discussed all treatment questions related to thrombotic thrombocytopenic purpura (TTP) using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method to appraise evidence and formulate recommendations.
More in haematology
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
